Navigation Links
Pro-Life Spokeswoman Objects to FDA Approval of 'Morning-After Pill' for Minors Without Prescription
Date:4/23/2009

WASHINGTON, April 23 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) announced late on April 22 that it has expanded over-the-counter access to the morning-after pill, Levonorgestrel or "Plan B," for 17-year-old minors as well as to adults. Deirdre McQuade, Assistant Director for Policy and Communications at the U.S. Conference of Catholic Bishops' Secretariat of Pro-Life Activities, objected to the move in the following statement:

"The FDA's court-driven decision to make Plan B available without a prescription to 17-year-old minors - as well as to adults - flies in the face of common sense. Levonorgestrel is a powerful drug, taken in two doses over a 12-hour period. It is 40 times more potent than comparable progestin-only birth control pills (Ovrette) for which a prescription is required.

"Wider access to Plan B could endanger the lives of newly-conceived children, and will put minors at risk for unnecessary side effects, undermine parental rights, and contribute to higher STD rates.

"Pregnancy is not a disease and fertility is not a pathological condition, so Plan B has no authentic therapeutic purpose, and can actually cause harm to women and their newly-conceived children.

"The FDA describes Plan B as 'a contraceptive drug.' Although Plan B can prevent fertilization, the manufacturer admits it may also prevent an embryo from implanting in the womb, which is essential to his or her continued survival. Since it takes several days for the growing embryo to reach the uterine lining and implant in the mother's womb, the child in his or her second week of life could die as a direct result of Plan B. This is properly understood as an early abortion.

"Without the benefit of a doctor's supervision, many teens will be unaware of this possible abortifacient action and the other risks posed by Levonorgestrel, particularly the risks from repeated use.'/>"/>

SOURCE U.S. Conference of Catholic Bishops, Secretariat for Pro-Life Activities
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FRC Action: Obama Administration Working to Overturn Pro-Life Laws in Other Countries
2. Bishops Pro-Life Official Gravely Concerned Over Threat to HHS Conscience Protection Regulation
3. FRC Commends Effort to Protect Pro-Life Riders, Prevent Taxpayer Funded Abortions
4. Cardinal Rigali to Congress: Keep Existing Pro-Life Laws
5. Massive Nationwide Pro-Life Postcard Campaign Underway
6. President Obamas Reversal of Mexico City Policy Very Disappointing, Says Pro-Life Committee Chair
7. Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation
8. Pennsylvania Most Pro-Life State in America, California Least, According to Americans United for Life State Rankings
9. A.L.L. Personhood Conference Features Pro-Life New Media Stars
10. Pro-Life Chair to Congress: We Cant Reduce Abortions By Promoting Abortion
11. DNC Party Crashers: Police Arrest 1 Pro-lifer at Black Caucus; Eject Operation Rescue Leader from DNC Interfaith Gathering at Colorado Convention Center
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Virtual maps for the blind 56801 1Virtual maps for the blind 56801 2Virtual maps for the blind 56801 3Changing the course of nature 3A Are fisheries directing the evolution of fish populations 3F 9874 1Changing the course of nature 3A Are fisheries directing the evolution of fish populations 3F 9874 2Stevens to host 2009 N J Inventors Hall of Fame Dinner 9871 1Stevens to host 2009 N J Inventors Hall of Fame Dinner 9871 2